Efficacy of antidepressants in the treatment of chronic nonspecific low back pain: a systematic review and meta-analysis

被引:0
|
作者
Nunes Filho, Marcio Jose Leao [1 ]
Barreto, Eduardo Silva Reis [1 ]
Antunes, Cesar Romero [1 ]
Alencar, Vinicius Borges [1 ]
Lins-Kusterer, Liliane Elze Falcao [1 ]
Azi, Liana Maria Torres de Araujo [1 ]
Kraychete, Durval Campos [1 ]
机构
[1] Univ Fed Bahia, BR-40110100 Salvador, BA, Brazil
关键词
antidepressive agents; chronic pain; clinical trials; low back pain; treatment outcome; QUALITY-OF-LIFE; DOUBLE-BLIND; 2ND-GENERATION ANTIDEPRESSANTS; DULOXETINE; BUPROPION; PLACEBO; TRIAL; OSTEOARTHRITIS; MANAGEMENT; EVENTS;
D O I
10.1080/17581869.2024.2408215
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Aim: This study reassesses the efficacy and safety of antidepressants in treating nonspecific chronic low back pain (NCLBP). Materials & methods: A systematic review was conducted following PRISMA guidelines, including randomized clinical trials (RCTs) from PubMed, Embase, Scopus, LILACS, SciELO and Cochrane CENTRAL, published through August 2024. Studies compared antidepressants with placebo or active comparators. The primary outcomes were pain relief and quality of life. Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42023307516. Results: Nine RCTs involving 1758 patients were analyzed. The antidepressants examined included duloxetine, escitalopram, bupropion, amitriptyline, imipramine and desipramine. Duloxetine 60 mg significantly reduced pain (MD = -0.57; 95% CI = -0.78 to -0.36) and improved quality of life compared with placebo, with side effects that were generally tolerable. Notably, higher doses of duloxetine (120 mg) were associated with an increase in adverse events. However, other antidepressants like amitriptyline and escitalopram demonstrated only modest or inconsistent effects. Conclusion: Duloxetine at 60 mg provides consistent pain relief and improves the quality of life in NCLBP, but higher doses increase adverse events. Escitalopram might offer modest benefits but should be considered a third-line treatment. Other antidepressants, such as amitriptyline, bupropion, imipramine and desipramine, have limited evidence supporting their efficacy and are associated with adverse effects. Chronic lower back pain is a condition that persists for a long time and can be difficult to manage. While the exact cause isn't always clear, it affects many people and can be difficult to manage. Doctors sometimes prescribe antidepressants, which are typically used for treating depression, but they may also help to reduce pain by influencing how the brain processes it.In this paper, we examined several studies to determine whether these antidepressants are effective in treating chronic lower back pain. We analyzed nine studies involving 1758 participants who were treated with different medications: bupropion, duloxetine, escitalopram, amitriptyline, imipramine and desipramine.Among these medications, duloxetine stood out as the most effective. It not only helped to relieve pain but also improved the participants' ability to carry out daily activities. Additionally, duloxetine had fewer side effects than some of the other medications, although it can still cause mild issues such as nausea.In conclusion, duloxetine appears to be a promising option for managing chronic lower back pain, as long as the appropriate dosage is used to balance pain relief and side effects.
引用
收藏
页码:437 / 451
页数:15
相关论文
共 50 条
  • [1] Efficacy, acceptability, and safety of antidepressants for low back pain: a systematic review and meta-analysis
    Ferraro, Michael C.
    Bagg, Matthew K.
    Wewege, Michael A.
    Cashin, Aidan G.
    Leake, Hayley B.
    Rizzo, Rodrigo R. N.
    Jones, Matthew D.
    Gustin, Sylvia M.
    Day, Richard
    Loo, Colleen K.
    McAuley, James H.
    SYSTEMATIC REVIEWS, 2021, 10 (01)
  • [2] Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain: a Systematic review and meta-analysis
    Weng, C.
    Xu, J.
    Wang, Q.
    Lu, W.
    Liu, Z.
    OSTEOARTHRITIS AND CARTILAGE, 2020, 28 (06) : 721 - 734
  • [3] Effectiveness of Acupuncture for Nonspecific Chronic Low Back Pain: A Systematic Review and Meta-Analysis
    Asano, Hitomi
    Plonka, Derek
    Weeger, Jacqueline
    MEDICAL ACUPUNCTURE, 2022, 34 (02) : 96 - 106
  • [4] Drug Therapy for the Treatment of Chronic Nonspecific Low Back Pain: Systematic Review and Meta-analysis
    Chung, Joanne W. Y.
    Zeng, Yingchun
    Wong, Thomas K. S.
    PAIN PHYSICIAN, 2013, 16 (06) : E685 - E704
  • [5] Systematic review of antidepressants in the treatment of chronic low back pain
    Staiger, TO
    Gaster, B
    Sullivan, MD
    Deyo, RA
    SPINE, 2003, 28 (22) : 2540 - 2545
  • [6] Efficacy and safety of antidepressants for pain in older adults: A systematic review and meta-analysis
    Narayan, Sujita W.
    Naganathan, Vasi
    Vizza, Lisa
    Underwood, Martin
    Ivers, Rowena
    Mclachlan, Andrew J.
    Zhou, Linyi
    Singh, Ramnik
    Tao, Shunyu
    Xi, Xiao
    Shaheed, Christina Abdel
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (12) : 3097 - 3118
  • [7] patients with chronic nonspecific low back pain: a systematic review with meta-analysis
    Miyamoto, Gisela C.
    Costa, Leonardo O. P.
    Cabral, Cristina M. N.
    BRAZILIAN JOURNAL OF PHYSICAL THERAPY, 2013, 17 (06) : 517 - 532
  • [8] Osteopathic manipulative treatment for nonspecific low back pain: a systematic review and meta-analysis
    Franke, Helge
    Franke, Jan-David
    Fryer, Gary
    BMC MUSCULOSKELETAL DISORDERS, 2014, 15
  • [9] Comparative efficacy of radiofrequency denervation in chronic low back pain: A systematic review and network meta-analysis
    Li, Han
    An, Junyan
    Zhang, Jun
    Kong, Weijian
    Yun, Zhihe
    Yu, Tong
    Nie, Xinyu
    Liu, Qinyi
    FRONTIERS IN SURGERY, 2022, 9
  • [10] Effectiveness of placebo interventions for patients with nonspecific low back pain: a systematic review and meta-analysis
    Strijkers, Rob H. W.
    Schreijenberg, Marco
    Gerger, Heike
    Koes, Bart W.
    Chiarotto, Alessandro
    PAIN, 2021, 162 (12) : 2792 - 2804